Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Treatment Resistent Cancers

Treatment Resistent Cancers

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.

Scientific reports·2026

Same author

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.

Cancer research·2026

Same author

Challenges and advances in drug resistance and tolerance in cancer.

Journal of experimental & clinical cancer research : CR·2026

Same author

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Nature communications·2026

Same author

Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability.

Biomaterials·2025

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

Trever G Bivona^1,2,3, Robert C Doebele⁴

¹Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

Nature Medicine

|May 6, 2016

Summary

Molecular targeted therapy offers cancer survival benefits, but complete tumor eradication is rare in advanced solid cancers. Understanding residual disease mechanisms is crucial for shifting from temporary control to a potential cure.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Mar 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Area of Science:

Oncology
Molecular Biology
Cancer Therapeutics

Background:

Molecular targeted therapy shows promise for improving cancer patient survival.
Complete and durable responses to targeted therapy are infrequent in advanced solid cancers.
Most targeted therapies leave residual disease, leading to tumor progression and limited survival.

Purpose of the Study:

To highlight the need for understanding the molecular basis of residual disease.
To propose strategies for minimizing or eliminating residual disease.
To advocate for a shift towards pre-emptive therapeutic paradigms.

Main Methods:

Discussion of current challenges in targeted cancer therapy.
Analysis of the limitations of existing therapeutic approaches.
Conceptual framework for a pre-emptive strategy against residual disease.

Main Results:

Residual disease is a common outcome of targeted therapy in advanced solid cancers.
Current approaches often result in temporary disease control rather than a cure.
Understanding residual disease is key to improving long-term patient survival.

Conclusions:

A deeper understanding of residual disease molecular mechanisms is essential.
A pre-emptive strategy targeting residual disease is proposed.
This shift aims to achieve chronic disease control or a cure for advanced solid cancers.